PTC Therapeutics, Inc (PTCT)

Etorro trading 970x250
PTC Therapeutics, Inc (PTCT) Logo

About PTC Therapeutics, Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey. Address: 100 Corporate Court, South Plainfield, NJ, United States, 07080

PTC Therapeutics, Inc News and around…

Latest news about PTC Therapeutics, Inc (PTCT) common stock and company :

PTC Therapeutics to Participate at Upcoming Virtual Investor Conference
16 Nov, 2021 Yahoo! Finance

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the 4th Annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 30 at 8:25 a.m. ET.

Is Therapeutics (NASDAQ:PTCT) Weighed On By Its Debt Load?
08 Nov, 2021 Yahoo! Finance

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

PTC Therapeutics Inc (PTCT) Q3 2021 Earnings Call Transcript
29 Oct, 2021 FinancialContent

PTCT earnings call for the period ending September 30, 2021.

PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates
28 Oct, 2021 Yahoo! Finance

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -6.18% and 16.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics Provides a Corporate Update and Reports Third Quarter 2021 Financial Results
28 Oct, 2021 Yahoo! Finance

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ending September 30, 2021.

The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
28 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner ...

Earnings Scheduled For October 28, 2021
28 Oct, 2021 FinancialContent

Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per ...

Where Do Hedge Funds Stand On PTC Therapeutics, Inc. (PTCT)?
26 Oct, 2021 Yahoo! Finance

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out […]

PTC Announces Expansion of Translarna™ Label to Include Ambulatory Patients as Young as 2 Years Old in Brazil
25 Oct, 2021 Yahoo! Finance

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Brazilian National Health Surveillance Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved the expansion of the indication of Translarna™ (ataluren) to include ambulatory children aged 2 to 5 years old with nonsense mutation Duchenne muscular dystrophy (Duchenne).1 This broadens the use beyond the previous age range of 5 years and older.

The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
24 Oct, 2021 FinancialContent

Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma ...

Earnings Preview: PTC Therapeutics (PTCT) Q3 Earnings Expected to Decline
21 Oct, 2021 Yahoo! Finance

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2021 Financial Results
14 Oct, 2021 Yahoo! Finance

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2021 financial results and provide an update on the company's business and outlook on Thursday, Oct. 28, at 4:30 p.m. ET.

PTC Therapeutics Celebrates Opening of Gene Therapy Manufacturing Facility
14 Oct, 2021 Yahoo! Finance

PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a ribbon-cutting ceremony to recognize the official opening of its new gene therapy manufacturing facility in Hopewell, N.J. today at 4 p.m. ET.

Tegsedi® Receives Innovative Drug Category Pricing in Brazil
11 Oct, 2021 Yahoo! Finance

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Tegsedi® (inotersen) has successfully received Category 1 classification from Câmara de Regulação do Mercado de Medicamentos - CMED (Drug Market Regulation Chamber) in Brazil. Category 1 classification is given to innovative treatments that provide greater efficacy than current standards of care. Category 1 allows for pricing in line with international markets.

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Recent Pullback in These 2 Stocks Is a ‘Buying Opportunity,’ Say Analysts
07 Oct, 2021 Yahoo! Finance

The investing game is rarely plain sailing. While no doubt investors would like the choices that make up their portfolio to always go up, the reality is more complicated. There are periods when even shares of the world’s most successful companies have been on a downward trajectory for one reason or another. While it’s no fun watching a stock you own drift to the bottom, any savvy investor knows that if the company’s fundamentals are sound to begin with, the pullback is often a gift in disguise.

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Sep, 2021 Yahoo! Finance

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept. 22, 2021, the company approved non-statutory stock options to purchase an aggregate of 51,400 shares of its common stock and 18,790 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 47 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation.

PTC Therapeutics' Rare Genetic Disease Gene Therapy Shows Durable Improvement Even At 5 Years
29 Sep, 2021 FinancialContent

PTC Therapeutics Inc(NASDAQ: PTCT)presented a new analysisof five-year results of gene therapy, PTC-AADC. The ...

Results Show Long-Lasting and Holistic Improvements in Children with AADC Deficiency Treated with PTC-AADC Gene Therapy
29 Sep, 2021 Yahoo! Finance

PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented a new analysis of five-year results that shows its novel gene therapy, PTC-AADC, leads to profound improvements in children with aromatic L-Amino acid decarboxylase (AADC) deficiency, a previously intractable, fatal and devastating rare disorder of the central nervous system.1-4 Children treated with PTC-AADC developed motor function and cognitive skills not previously seen, such as holding up their head, sitting or standing with support and

58 Biggest Movers From Yesterday
24 Sep, 2021 FinancialContent

Gainers MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) shares surged 73.4% to close at $12.80 on Thursday following news the ...

12 Health Care Stocks Moving In Thursday's Intraday Session
23 Sep, 2021 FinancialContent

Gainers TransCode Therapeutics (NASDAQ:RNAZ) stock rose 94.3% to $5.09 during Thursday's regular session. TransCode ...

38 Stocks Moving In Thursday's Mid-Day Session
23 Sep, 2021 FinancialContent

Gainers MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) shares jumped 101% to $14.87 following news the company will buy ZACC ...

The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
23 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

PTC Therapeutics to Host Conference Call to Discuss Results of PTC518 Phase 1 Study for Huntington's Disease Program
20 Sep, 2021 Yahoo! Finance

PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call to discuss the positive results from the PTC518 Phase 1 healthy volunteer study. The new results include HTT mRNA and protein lowering, as well as PTC518 exposure levels in the cerebrospinal fluid, consistent with the compound penetrating the blood-brain barrier and not being effluxed out of the brain.

STRIDE Data Show Translarna™ Delays Loss of Ambulation by More Than Five Years in Boys with Nonsense Mutation Duchenne Muscular Dystrophy
20 Sep, 2021 Yahoo! Finance

PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented real-world results from the STRIDE patient registry demonstrating that treatment with Translarna™ (ataluren) delays loss of ambulation by more than five years in boys with nonsense mutation Duchenne muscular dystrophy (nmDMD) compared to standard of care (SoC) alone. Pulmonary function decline was also delayed by 1.8 years in those treated with Translarna and SoC.

Aadi Bioscience Appoints Emma Reeve to its Board of Directors
13 Sep, 2021 FinancialContent
How The Pieces Add Up: ESML Headed For $47
08 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares ESG Aware MSCI USA Small-Cap ETF (ESML), we found that the implied analyst target price for the ETF based upon its underlying holdings is $46.57 per unit.

PTC Therapeutics Recognizes 2021 STRIVE Awards Recipients for Initiatives Supporting Duchenne Patient Community
07 Sep, 2021 Yahoo! Finance

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the three recipients who will receive funding through the company's STRIVE Awards program. The global STRIVE Awards program provides grants to non-profit organizations serving the Duchenne muscular dystrophy community.

PTC Therapeutics, Inc (PTCT) is a NASDAQ Common Stock listed in , ,

970x250